This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

Compounded Tirzepatide and the Shortage That Ended

A shortage list let compounders sell a famous drug, the list changed, and a court agreed the government was allowed to change it.

A clipboard holding a printed list with one line struck through, resting on a pharmacy counter beside empty glass vials.

The way a compounded copy of a famous drug gets to exist, legally, is that the real drug shows up on a list. Compounding a copy of an FDA-approved drug is ordinarily prohibited, but federal law has a shortage exception: while a drug sits on the FDA’s drug shortage list, state-licensed 503A pharmacies and registered 503B outsourcing facilities may make it. Tirzepatide, Eli Lilly’s injectable GLP-1, went on that list in 2022, when demand outstripped supply. A lot of people started making it.

Then it came off. The FDA declared the tirzepatide shortage resolved on October 2, 2024, reaffirmed that on December 19, 2024 after a court remand, and gave compounders grace periods that ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. The industry’s trade group sued and lost, and in September 2026 it was reported that the Fifth Circuit had upheld the FDA. So the plain answer on where compounded tirzepatide stands is that the exception that made the mass-market version legal is gone, and a federal appeals court has said the FDA was allowed to take it away.

How a shortage list became a business license

The exception is narrow on paper. As the law firm ArentFox Schiff summarizes Section 503B, an outsourcing facility may compound large volumes from bulk drug substances, without individual prescriptions, if the drug appears on the shortage list “at the time of compounding, distribution, and dispensing.” (That is three separate moments, each of which has to land on the right side of a list.) It is not a general right to compound popular medicines. It is a permission that lasts while a web page says a particular thing.

And yet the GLP-1 compounding market grew into a multibillion-dollar sub-industry on that permission. Which makes sense, I suppose. If you tell an industry it may sell a drug millions of people want for as long as a government list calls the drug scarce, you have basically created a business whose central asset is a line of text.

Here is an invented case, and it is purely invented. A facility compounds a batch at 4 p.m. while tirzepatide is listed. The list updates overnight. The batch ships at 9 a.m. It was legal when made and is not legal when shipped, so in some sense it became illegal in a box on a loading dock. If the list flickered on and off every hour, the optimal business would be a lab that compounds only on the hour, a courier who drives only on the half hour, and a lawyer who sleeps never.

The grace periods exist partly because of this. Real operations do not switch off when a page refreshes (no matter how many times a compliance officer hits refresh).

Why the tirzepatide shortage ended twice

The shortage ended on October 2, 2024. Then it ended again.

Between those dates there was a court remand (the sources here do not spell out its details), the FDA looked again, and on December 19, 2024 tirzepatide injection products were removed from the list “by declaratory order.” A declaratory order, in this case, is the FDA formally writing down that it still meant what it said in October. It is a little Groundhog Day, except the weather never changed.

What the FDA looked at was Lilly’s expanded manufacturing capacity, alongside information from manufacturers, compounders, patients, healthcare professionals, telehealth companies and others. I assume the conversation at a lot of compounders that fall went something like: “Is it still short?” “Lilly says no.” “Is Lilly the one we’re asking?”

That last question became the lawsuit.

What the compounders argued in court

The Outsourcing Facilities Association, or OFA, filed federal lawsuits challenging the FDA’s determinations that both the tirzepatide and semaglutide shortages were over. (The semaglutide story has its own article on this site, and I will leave it there.) This is the part where people like me, who read administrative procedure filings voluntarily and then wonder why the dinner party went quiet, get excited.

OFA’s first argument was about procedure. It said the shortage resolution was really rulemaking, not adjudication, because it “declared the law going forward” for the whole compounding industry. Rules under the Administrative Procedure Act generally need notice and comment. The FDA had not done notice and comment. So, OFA argued, the decision was invalid.

The second argument was about facts. OFA said the original removal was based “entirely on Lilly’s representation of the situation, rather than on reality,” with “scant explanation,” and that the FDA doubled down even after seeing evidence of surging demand, regional and national scarcity, and delays filling prescriptions. Is a shortage a fact about pharmacies, or a rule about compounders? OFA’s case needed it to be both.

On March 5, 2025, Judge Mark Pittman entered a sealed opinion denying OFA’s motion for a preliminary injunction. Part of the evidentiary fight, per later reporting on the appeal, involved access-problem data collected through a Hims & Hers website (a telehealth company, which I am sure approached the question of whether compounding should continue in a spirit of pure scholarship). The FDA discounted those submissions because they did not reliably show when the problem happened, where the user was, why they could not get the drug, or whether one person had filed several times. That is a fairly complete list of things a survey is for.

How the Fifth Circuit settled it

The appeal was pending before the Fifth Circuit as of May 2026 (appellate courts keep their own calendar, and it is not a fast one). In September 2026 it was reported that the court upheld the FDA’s determinations removing both semaglutide and tirzepatide from the shortage list. The notice-and-comment argument did not carry the day, or whatever the precise doctrinal phrasing turns out to be once everyone has read the opinion closely.

The point is that the shortage being over is now a settled legal fact. Whether it is a settled fact about the world is a slightly different question.

Three ways to read the compounded tirzepatide fight

There are, roughly, three ways to read this.

The first is that the system worked. A real supply problem appeared in 2022, compounders filled the gap under an exception built for exactly that, Lilly built capacity, the FDA checked, the exception closed, and courts confirmed it. Bridges are supposed to end.

The second is OFA’s reading: the FDA leaned on the one party with the most to gain from the list closing, and waved off messier evidence from patients and pharmacies. You and I both know that “the manufacturer can now make enough” and “everyone who wants it can afford what it costs” are different sentences. A shortage list only has room for one of them. The courts said the FDA could pick, which is not quite the same as saying it picked right.

The third is the least comfortable. The shortage list was never built to hold up a multibillion-dollar industry, and the demand it was holding up did not leave when the listing did. A secret shopper study identified 75 businesses still selling compounded GLP-1s, and 86.7% of them sold compounded tirzepatide. The FDA sent warning letters to telehealth sellers in three rounds, in September 2025, February 2026 and June 2026. It found that one compounder, Empower Clinic Services, made tirzepatide and semaglutide products the agency called essentially copies of the approved ones, which is the precise thing the ordinary rule forbids. Compounders now face lawsuits from drug makers and enforcement from the FDA at once, sort of thing.

And underneath it all, compounded tirzepatide has never been reviewed by the FDA for safety, effectiveness, purity or stability, even from a fully licensed pharmacy. The trial numbers people cite, like SURMOUNT-1, come from Lilly’s own injectable. That was true when the drug was listed, too. The list never measured the product. It measured the scarcity.

I don’t know how this ends for the remaining sellers. It is not settled. What is settled is the thing that started it: for a few years a whole industry ran on a line on a list, and the line is gone.

The customers were never on the list.

Sources

  1. Compounded Tirzepatide: Meaning, Risks, Regulator Warnings
  2. Fifth Circuit Upholds FDA on GLP-1 Shortage Decisions
  3. The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
  4. GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner
  5. Compounding After a Drug Leaves the Shortage List
  6. Semaglutide Salt Forms: Why the Base Matters
  7. Compounded GLP-1s: Why doctors worry and the FDA is cracking down
  8. FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’ - BioSpace
  9. Major Update on GLP-1 Litigation involving Compounding ...
  10. Alert to All Compounders: Update in FDA Tirzepatide Litigation - Frier Levitt
  11. OFA v. FDA: The latest
  12. FDA Warning Letters to Telehealth Companies Selling Compounded Drugs
  13. Businesses continue to sell compounded semaglutide, tirzepatide

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.

Read next